english.prescrire.org > Spotlight > 100 most recent > Abaloparatide (Eladynos°) in postmenopausal osteoporosis

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Abaloparatide (Eladynos°) in postmenopausal osteoporosis

 Marketing Authorisations  In postmenopausal women, the main strategies for preventing fractures due to bone fragility are fall prevention and regular physical exercise. When pharmacological prevention is chosen, the first-choice option is a bisphosphonate such as alendronic acid. Abaloparatide, a parathyroid hormone agonist with a similar mechanism of action to teriparatide, has been authorised in the European Union for use in postmenopausal women with osteoporosis who are at "increased" risk of fracture.
Full article available for download by subscribers

 ©Prescrire 1 July 2025

Source: "Abaloparatide (Eladynos°) in postmenopausal osteoporosis" Prescrire Int 2025; 34 (272): 178-179. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Raloxifene and teriparatide
in the prevention of
osteoporotic fractures
in postmenopausal women"
Prescrire Int 2024;